SK Life Science (subsidiary of SK Biopharmaceuticals, part of SK Group) will present 10 new posters on cenobamate, its anti-seizure medication, at the upcoming 2025 American Epilepsy Society meeting. The data covers clinical efficacy, safety, pharmacokinetics, mortality risk, and healthcare resource utilization. Cenobamate, marketed as XCOPRI in the US, targets focal seizures and is expanding globally through various partnerships. Despite new treatments, about 40% of people with epilepsy still experience uncontrolled seizures. This continues SK's push to innovate in the CNS drug market, which may be worth noting for anyone tracking pharma pipeline news connected to SK Group.